A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine
Status:
Completed
Trial end date:
2020-08-13
Target enrollment:
Participant gender:
Summary
Study STS101-002 is a randomized, double-blind, parallel group, placebo-controlled,
multicenter study to evaluate the efficacy, safety, and tolerability of single doses of
STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine